Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar;14(1):109-26.
doi: 10.1007/s11864-012-0222-4.

Novel therapies for the treatment of advanced prostate cancer

J M Clarke  1 , A J Armstrong
Affiliations
Review

Novel therapies for the treatment of advanced prostate cancer

J M Clarke et al. Curr Treat Options Oncol. 2013 Mar.

Abstract

In recent years, great success has been achieved on many fronts in the treatment of men with metastatic castration-resistant prostate cancer (CRPC), including novel chemotherapeutics, immunotherapies, bone microenvironment-targeted agents, and hormonal therapies. Numerous agents are currently in early-phase clinical trial development for the treatment of advanced prostate cancer. These novel therapies target several areas of prostate tumor biology, including the upregulation of androgen signaling and biosynthesis, critical oncogenic intracellular pathways, epigenetic alterations, and cancer immunology. Importantly, the characterization of the prostate cancer genome offers the potential to exploit conserved genetic alterations, which may increase the efficacy of these targeted therapies. Predictive and prognostic biomarkers are urgently needed to maximize therapeutic efficacy and safety of these promising new treatments options in prostate cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Intracellular signaling pathways involved in prostate cancer and opportunities for targeted therapies [12]. AR signaling is modulated by the MAPK, PI3K/AKT/mTOR, and b-catenin signaling pathways. Androgen directed agents: enzalutamide, Orteronel, ARN509, EPI509, Galeterone. Signal transduction inhibitors: cabozantinib, GDC-0068, MK2206, XL-147, BKM-120, dasatinib. The TMPRSS2:ETS fusion results in over expression of the ETS gene product which binds to the AR. Tumor suppressor gene transcription is regulated by epigenetic alterations including histone modification and CpG methylation. Epigenetic Alterations: Vorinostat, Pano-binostat, Azacitidine. EMT inhibition: Vismodegib (GDC-0449). Immune check point blockade: Ipilimumab, CT-011. Reprinted with permission. © 2011 American Society of Clinical Oncology. All rights reserved.
Fig. 2
Fig. 2
Frequency of select genetic alterations in CRPC exomes. AR Androgen receptor, APC adenomatous poliposis coli, ZFHX3 zinc finger homeobox 3, RB1 retinoblastoma 1, TP53 tumor protein 53, PTEN phosphatase and tensin homolog, BRCA2 breast cancer type 2 susceptibility. Data modified from Grasso et al. 2012 [1••].
See this image and copyright information in PMC

References

    1. Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239–43. Characterizes common mutations found in exomes of prostate cancer. - PMC - PubMed
    1. Friedlander TW, Roy R, Tomlins SA, et al. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res. 2012;72:616–25. Describes comprehensive gene methylation and copy number alterations in prostate cancer. - PubMed
    1. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18:11–22. Defines the prostate cancer transcriptome and profile copy number alteration involved in many oncogenic pathways. - PMC - PubMed
    1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22. - PubMed
    1. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54. - PubMed

Substances